SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PAVM reported Third Quarter 2026 results. The price and volatility reaction is pending.
PAVMearnings

Earnings reactions, page 2

PAVmed Inc. (PAVM) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP revenue was $41 thousand for the three months ended September 30, 2026.
  • GAAP operating expenses were approximately $6.8 million ($6,768 thousand) for the three months ended September 30, 2026.
  • Non-GAAP adjusted loss was approximately $1.2 million, or $(0.19) non-GAAP adjusted loss per common share, basic and diluted, for the three months ended September 30, 2026.
  • GAAP net loss as reported was $(11,655) thousand for the three months ended September 30, 2026.
  • Non-GAAP EBITDA was $(11,906) thousand for the three months ended September 30, 2026.
  • Cash and cash equivalents totaled $8.9 million, including $5.3 million of restricted cash, as of September 30, 2026.

Notes

Financial results for the third quarter ended September 30, 2026 are reported as preliminary.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →